Literature DB >> 26069282

In Reply.

Yusuke Takagi1, Yukio Hosomi2, Masahiko Shibuya2, Hiroaki Okamoto3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26069282      PMCID： PMC4492246          DOI： 10.1634/theoncologist.2015-0070

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

1.  A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer.

Authors:  Yusuke Takagi; Yukio Hosomi; Kuniko Sunami; Yoshiro Nakahara; Yusuke Okuma; Makiko Yomota; Tsuneo Shimokawa; Makoto Nagamata; Mari Iguchi; Hiroaki Okamoto; Tatsuru Okamura; Masahiko Shibuya
Journal:  Oncologist       Date:  2014-09-26

2.  Total Plasma Homocysteine Level Assessment and Timing of Folate/B12 Supplementation Prior to Initiation of Pemetrexed-Based Chemotherapy for Nonsquamous Non-Small Cell Lung Cancer Patients: An Irrelevant Investigation, an Unnecessary Delay, or Both?

Authors:  Navneet Singh; Venkata Nagarjuna Maturu; Digambar Behera
Journal:  Oncologist       Date:  2015-06-11

3.  Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Authors:  Clet Niyikiza; Sharyn D Baker; David E Seitz; Jackie M Walling; Katrina Nelson; James J Rusthoven; Sally P Stabler; Paolo Paoletti; A Hilary Calvert; Robert H Allen
Journal:  Mol Cancer Ther       Date:  2002-05       Impact factor: 6.261

4.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

5.  Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy.

Authors:  Navneet Singh; Ashutosh N Aggarwal; Jyotdeep Kaur; Digambar Behera
Journal:  Am J Clin Oncol       Date:  2017-02       Impact factor: 2.339

6.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.